
Director · Organogenesis Holdings Inc. · Class A Common Stock
Open-market sale
$1.0M reported value · 7.2% of prior position
Disclosed 2 business days after execution (deadline: 2)
3 prior trades recorded in this security
No clustered activity in the dataset
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 24 | Grow BrianChief Commercial Officer | Option exercise | M | — 958 sh | Apr 24, 2026 traded Jan 10, 2025 | |
| 24 | Grow BrianChief Commercial Officer | Option exercise | M | $1,188 958 sh | Apr 24, 2026 traded Jan 10, 2025 | |
| 34 | Leibowitz Arthur SDirector | Open-market purchase | BUY | $13K 5,000 sh | Mar 11, 2026 traded Mar 9, 2026 | |
| 34 | Driscoll Michael JosephDirector | Open-market purchase | BUY | $27K 10.0K sh | Mar 11, 2026 traded Mar 9, 2026 | |
| 9 | Cavorsi RobertVice President, Strategy | Tax withholding | F | $2,247 700 sh | Mar 3, 2026 traded Mar 1, 2026 | |
| 9 | Cavorsi RobertVice President, Strategy | Tax withholding | F | $21K 5,432 sh | Feb 20, 2026 traded Feb 18, 2026 | |
| 9 | Cavorsi RobertVice President, Strategy | Grant or award | A | — 53.5K sh | Feb 20, 2026 traded Feb 18, 2026 | |
| 17 | Francisco DavidChief Financial Officer | Grant or award | A | — 195.3K sh | Feb 20, 2026 traded Feb 18, 2026 | |
| 13 | Francisco DavidChief Financial Officer | Grant or award | A | — 43.6K sh | Feb 20, 2026 traded Feb 18, 2026 | |
| 17 | Grow BrianChief Commercial Officer | Grant or award | A | — 234.4K sh | Feb 20, 2026 traded Feb 18, 2026 | |
| 13 | Grow BrianChief Commercial Officer | Grant or award | A | — 48.3K sh | Feb 20, 2026 traded Feb 18, 2026 | |
| 9 | Grow BrianChief Commercial Officer | Tax withholding | F | $45K 11.8K sh | Feb 20, 2026 traded Feb 18, 2026 | |
| 17 | Bilbo PatrickChief Operating Officer | Grant or award | A | — 210.9K sh | Feb 20, 2026 traded Feb 18, 2026 | |
| 9 | Bilbo PatrickChief Operating Officer | Grant or award | A | — 48.6K sh | Feb 20, 2026 traded Feb 18, 2026 | |
| 12 | Bilbo PatrickChief Operating Officer | Tax withholding | F | $62K 16.2K sh | Feb 20, 2026 traded Feb 18, 2026 | |
| 9 | Bilbo PatrickChief Operating Officer | Grant or award | A | — 120.3K sh | Feb 20, 2026 traded Feb 18, 2026 | |
| 17 | Gillheeney Gary S.Director, President and CEO | Grant or award | A | — 890.6K sh | Feb 20, 2026 traded Feb 18, 2026 | |
| 15 | Gillheeney Gary S.Director, President and CEO | Tax withholding | F | $347K 90.4K sh | Feb 20, 2026 traded Feb 18, 2026 | |
| 9 | Gillheeney Gary S.Director, President and CEO | Grant or award | A | — 507.8K sh | Feb 20, 2026 traded Feb 18, 2026 | |
| 17 | Montecalvo Antonio S.Vice President, Health Policy | Grant or award | A | — 40.6K sh | Feb 20, 2026 traded Feb 18, 2026 |
Read directly from the primary public document; every field below is as reported by the filer.
Value = shares × reported price per share
= $1,027,060
Nussdorf Glenn H filed this Form 4 reporting a open-market sale of ORGO on Dec 16, 2025. It became public on Dec 18, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
No field has changed since this record was first ingested.
No material filings recorded for this issuer.